Product Description
Bencycloquidium bromide nasal spray is effective and safe for persistent allergic rhinitis (Sourced from: https://pubmed.ncbi.nlm.nih.gov/32623510/)
Mechanisms of Action: M1 Antagonist,M3 Antagonist Binder
Novel Mechanism: Yes
Modality: N/A
Route of Administration: Nasal,Inhalant
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Yingu Pharmaceutical
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Sneezing
Phase 1: Chronic Obstructive Pulmonary Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CTR20211344 | P3 |
Recruiting |
Sneezing |
None |
|
CTR20212431 | P1 |
Not yet recruiting |
Chronic Obstructive Pulmonary Disease |
None |